Skip to main content

Correction to: PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas

Correction to: Genome Biol 21, 181 (2020)

https://doi.org/10.1186/s13059-020-02092-2

Following publication of the original paper [1], the authors identified errors the paper.

Under the heading Whole-Exome Sequencing Reveals The Mutational Landscape in the results section, the following text has been updated. The updated text is displayed in bold typeface.

In contrast to the relatively small number of recurrent mutations, EGFR-mutant tumors had complex genomes by DNA copy number analysis (Fig. 2b). Significant focal amplifications and deletions, identified by GISTIC2 35, were evident in regions with known cancer genes, for example significant focal Cdkn2a deletions (GISTIC q-value = 1.39 × 10− 5) were evident and EGFRvIII (in Col1a1 locus, GISTIC q-value = 0.017) was recurrently amplified. Significantly recurrent focal deletions were present in a novel putative glioma driver Adgrl2 (GISTIC q-value = 2.19 × 10− 6, Additional File 4: Table S3). Although focal deletions in Nlrp1b were present, recent evidence suggests these represent a strain-specific germline variant rather than being oncogenic [2]. Several of the most significantly mutated genes were also in regions with frequent deletions, including Trp53, Tead2 and Uimc1, supporting putative tumor suppressive roles (Fig. 3i).

The caption of Fig. 3 has also been updated. The correct caption is supplied below. The updated text is displayed in bold typeface.

Figure 3. Conditional PiggyBac transposon mutagenesis substitutes for genomic instability in EGFRvIII-mutant gliomas. A. Mouse constructs for PiggyBac transposition. The ATP1-S2 transposon line, with 20 copies per cell. Conditional PiggyBac transposase targeted to Rosa26 (tissue-specific PiggyBac transposase, TSPB), SA = splice acceptor; SD = splice donor; CAG = CAG promoter; SB = Sleeping Beauty; PB = PiggyBac inverted repeats; iPBase = insect version of the PiggyBac transposase. The transposon can activate gene transcription if it inserts in the same orientation as the gene, usually in a 5′ position. Gene inactivation can occur if the transposon inserts in the body of the gene as a consequence of gene trapping which can occur in either orientation because of the presence of two splice acceptors and bidirectional poly(A) (pA) sites. B. Outline of the experimental design: quadruple transgenic mice conditionally activate EGFRvIII expression and PiggyBac transposition in the central nervous system. Resultant tumors are examined molecularly by whole-exome sequencing and mapping of transposon insertions. C. Histology of EGFRvIII-PB tumors; although not statistically significant, a higher proportion of grade IV brain tumors are observed compared with tumors lacking transposition. D. Immunostaining profile of a typical grade III brain glioma from an EGFRvIII-PB mouse, showing strong expression of neural stem and transit-amplifying cell markers. Scale bar corresponds to 2.8 mm for top panel, and 200 μm for all other panels. E. Representative karyotype of EGFRvIII-only and EGFRvIII-PB brain tumors, showing polyploidy in the non-PB tumor. F. Chromosomal aberrations in EGFRvIII-only and EGFRvIII-PB tumors (n = 3 and n = 5 tumors respectively; mean chromosomal aberrations 19 vs 6.4, p = 0.013, unpaired two-tailed t-test; plots show mean +/− standard deviation). G. Copy number profile of EGFRvIII-PB tumors (n = 20) with focal amplifications and deletions in key genes highlighted. H. Mutational profile of 20 EGFRvIII-PB brain and spinal tumors from whole-exome sequencing. I. Key genes identified in gliomas, either as significantly mutated from MuSiC or copy number altered from GISTIC2, across all mouse brain and spinal tumors in both cohorts (note Nlrp1b deletions are however a germline variant [2]); each column represent one tumor.

In addition, the authors identified an error in the author name of Yoon Ha Choi.

The incorrect author name is: Yoonha Choi

The correct author name is: Yoon Ha Choi

References

  1. 1.

    Noorani I, de la Rosa J, Choi Y, et al. PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas. Genome Biol. 2020;21:181. https://doi.org/10.1186/s13059-020-02092-2.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Mueller S, et al. Linkage of genetic drivers and strain-specific germline variants confound mouse cancer genome analyses. Nat Commun. 2020; In press.

Download references

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Imran Noorani or Allan Bradley.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Noorani, I., de la Rosa, J., Choi, Y.H. et al. Correction to: PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas. Genome Biol 21, 206 (2020). https://doi.org/10.1186/s13059-020-02127-8

Download citation